DCGI has already given emergency use authorization (EUA) to BBIL for the intranasal vaccine. BBIL had in September this year applied for DCGI's approval for market authorization of its "Five Arms" intranasal heterologous booster dose, and it has now announced that iNCOVACC (BBV154) has received approval under Restricted Use in Emergency Situation for ages 18 and above.
\
\
